Clinical Daily Summary
Clinical Daily Summary: What Happened on October 24, 2026
Enhertu fails as neoadjuvant treatment in early breast cancer
Five-year melanoma data favor relatlimab plus nivolumab. In an exploratory bladder cancer study, visugromab added to nivolumab produced more responses than nivolumab plus placebo.
Today in brief
Enhertu failed as a neoadjuvant treatment for early breast cancer.1 A five-year analysis in advanced melanoma found continued benefit from relatlimab plus nivolumab over nivolumab alone.2
In an exploratory bladder cancer study, more patients had complete pathologic responses with visugromab plus nivolumab than with nivolumab plus placebo.3
Five-year melanoma analysis finds continued survival benefit
After at least 57.3 months of follow-up, relatlimab plus nivolumab continued to improve progression-free, overall and melanoma-specific survival over nivolumab alone in a prespecified analysis.2 The trial enrolled 714 patients with advanced melanoma.2
Hazard ratios favored the combination for progression-free survival, overall survival and melanoma-specific survival: 0.77, 0.78 and 0.71, respectively.2 The safety profile remained consistent with earlier reports.2
Among patients whose tumors had at least 1% PD-L1 expression, higher levels of LAG-3-positive CD8 cells were associated with worse outcomes on nivolumab alone.2 Primary resistance was less prevalent with added relatlimab than with nivolumab alone.2 The authors said the findings support the possibility that relatlimab can overcome resistance to nivolumab mediated by LAG-3.2
Visugromab combination shows higher response rates in exploratory bladder study
Complete pathologic responses occurred in 5 of 15 evaluable patients given visugromab plus nivolumab, compared with 1 of 13 given nivolumab plus placebo in GDFATHER-NEO.3 The exploratory Phase 2a study enrolled 31 patients with newly diagnosed muscle-invasive bladder cancer who were unable or unwilling to receive cisplatin.3
Major pathologic response rates were 60% with visugromab and 23% with placebo. Radiographic response rates were 60% and 15%, respectively.3 Participants received three treatment cycles in a sequentially assigned, nonrandomized study.3
Grade 3 or 4 treatment-related adverse events affected 13% of the combination group and 20% of the placebo group.3 There were no treatment-related discontinuations or surgery delays.3 The authors said the results support further assessment of visugromab in muscle-invasive bladder cancer.3